Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amanda Mixon

Physician Assistant, Medical Fort Collins, CO Physician Assistant

NPI 1174795017 CMS profile 10428661

2121 E Harmony Rd Unit 230, Fort Collins, CO 80528

Open in the dashboard

General payments

$341,961

690 records reported · program years 2021–2025

Research payments

$6,563

Paid to them · 1 record reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Mixon of Fort Collins, CO is reported in the CMS Open Payments database as having received $341,961 across 690 general payments and $6,563 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,174 18
2024 General $30,052 78
2023 General $91,740 170
2022 General $125,158 248
2021 General $93,837 176
2021 Research $6,563 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Mixon
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Amanda Mixon were reported at $1,174. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Amanda Mixon Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $93,837 $156 $41–$563 $132
2022 $125,158 $185 $55–$649 $149
2023 $91,740 $199 $58–$717 $160
2024 $30,052 $206 $62–$740 $164
2025 $1,174 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $153,464 282 payments
  2. Lilly USA, LLC $55,668 128 payments
  3. Janssen Scientific Affairs, LLC $40,218 48 payments
  4. Janssen Biotech, Inc. $27,766 49 payments
  5. Genzyme Corporation $11,912 38 payments
  6. AstraZeneca Pharmaceuticals LP $11,036 44 payments
  7. Amgen Inc. $10,696 32 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $10,318 20 payments
  9. Pfizer Inc. $7,462 7 payments
  10. Eli Lilly and Company $4,500 2 payments
  11. Other $8,921 40 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $193,162 166 payments
  2. Travel and Lodging $83,325 231 payments
  3. Consulting Fee $46,352 28 payments
  4. Food and Beverage $14,658 260 payments
  5. Honoraria $4,365 3 payments
  6. Education $99 2 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $131,882 246 payments
  2. TREMFYA $61,952 87 payments
  3. SIMPONI ARIA $57,226 76 payments
  4. TALTZ $42,954 86 payments
  5. STELARA $41,008 48 payments
  6. KEVZARA $10,545 34 payments
  7. OFEV $10,318 20 payments
  8. Otezla $10,123 20 payments
  9. SAPHNELO $9,376 20 payments
  10. XELJANZ $6,312 6 payments
  11. Other $17,288 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $6,563 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

818

Median for Physician Assistant: 241

Drug cost

$387,060

Median for Physician Assistant: $4,110

Branded share of claims

22%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Orencia Clickject Abatacept Brand 22 $125,759
Enbrel Etanercept Brand 13 $109,808
Humira(Cf) Pen Adalimumab Brand 11 $76,538
Kevzara Sarilumab Brand 13 $56,932
Hydroxychloroquine Sulfate Generic 209 $8,200
Methotrexate Methotrexate Sodium Brand 121 $2,953
Febuxostat Generic 18 $1,556
Prednisone Generic 156 $1,238
Duloxetine Hcl Generic 38 $770
Leflunomide Generic 13 $757

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$505,316

Of which drugs: $462,436

Medicare patients

183

Average age 71

Services billed

24,283

146 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 62%
Osteoporosis 34%
Depression 26%
Chronic kidney disease 16%
Cancer 15%
Diabetes 14%
Ischemic heart disease 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $10,318
$10,318 — —
TALTZ
  • Lilly USA, LLC $5,744
$5,744 — —
TREMFYA
  • Janssen Biotech, Inc. $4,158
$4,158 — —
SIMPONI ARIA
  • Janssen Biotech, Inc. $4,158
$4,158 — —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $2,597
$2,597 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

691 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record